Perceptive Advisors LLC Trims Stock Holdings in Palvella Therapeutics, Inc. $PVLA

Perceptive Advisors LLC trimmed its position in Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 32.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 266,287 shares of the company’s stock after selling 128,806 shares during the period. Perceptive Advisors LLC’s holdings in Palvella Therapeutics were worth $27,872,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. First Light Asset Management LLC purchased a new stake in shares of Palvella Therapeutics in the third quarter worth $33,949,000. Summit Partners Public Asset Management LLC grew its stake in shares of Palvella Therapeutics by 1,016.0% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock worth $40,761,000 after acquiring an additional 354,525 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Palvella Therapeutics by 202.0% in the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock worth $31,010,000 after acquiring an additional 330,847 shares during the last quarter. State Street Corp grew its stake in shares of Palvella Therapeutics by 206.3% in the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after acquiring an additional 283,211 shares during the last quarter. Finally, Jennison Associates LLC grew its stake in shares of Palvella Therapeutics by 262.4% in the fourth quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock worth $40,558,000 after acquiring an additional 280,573 shares during the last quarter. 40.11% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on PVLA. Stifel Nicolaus set a $250.00 target price on Palvella Therapeutics in a research note on Tuesday, February 24th. Chardan Capital reissued a “buy” rating and issued a $240.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Wall Street Zen cut Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. BTIG Research increased their target price on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Finally, Mizuho increased their target price on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $199.53.

Palvella Therapeutics Price Performance

Shares of NASDAQ:PVLA opened at $112.63 on Thursday. The company has a market cap of $1.62 billion, a P/E ratio of -27.01 and a beta of -0.15. Palvella Therapeutics, Inc. has a 1 year low of $20.20 and a 1 year high of $151.18. The stock’s fifty day moving average price is $118.97 and its 200-day moving average price is $108.85.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, sell-side analysts anticipate that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current year.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.